Literature DB >> 18606656

Delayed contraction of the CD8+ T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin.

Mirjana Grujic1, Jan P Christensen, Maria R Sørensen, Magnus Abrink, Gunnar Pejler, Allan R Thomsen.   

Abstract

We previously reported that the lack of serglycin proteoglycan affects secretory granule morphology and granzyme B (GrB) storage in in vitro generated CTLs. In this study, the role of serglycin during viral infection was studied by infecting wild-type (wt) mice and serglycin-deficient (SG(-/-)) mice with lymphocytic choriomeningitis virus (LCMV). Wt and SG(-/-) mice cleared 10(3) PFU of highly invasive LCMV with the same kinetics, and the CD8(+) T lymphocytes from wt and SG(-/-) animals did not differ in GrB, perforin, IFN-gamma, or TNF-alpha content. However, when a less invasive LCMV strain was used, SG(-/-) GrB(+) CD8(+) T cells contained approximately 30% less GrB than wt GrB(+) CD8(+) T cells. Interestingly, the contraction of the antiviral CD8(+) T cell response to highly invasive LCMV was markedly delayed in SG(-/-) mice, and a delayed contraction of the virus-specific CD8(+) T cell response was also seen after infection with vesicular stomatitis virus. BrdU labeling of cells in vivo revealed that the delayed contraction was associated with sustained proliferation of Ag-specific CD8(+) T cells in SG(-/-) mice. Moreover, wt LCMV-specific CD8(+) T cells from TCR318 transgenic mice expanded much more extensively in virus-infected SG(-/-) mice than in matched wt mice, indicating that the delayed contraction represents a T cell extrinsic phenomenon. In summary, the present report points to a novel, previously unrecognized role for serglycin proteoglycan in regulating the kinetics of antiviral CD8(+) T cell responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606656     DOI: 10.4049/jimmunol.181.2.1043

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Perforin plays an unexpected role in regulating T-cell contraction during prolonged Listeria monocytogenes infection.

Authors:  Nathan W Schmidt; Aaruni Khanolkar; Lisa Hancox; Jonathan W Heusel; John T Harty
Journal:  Eur J Immunol       Date:  2012-01-18       Impact factor: 5.532

2.  A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway.

Authors:  Fabio Rabelo Melo; Ida Waern; Elin Rönnberg; Magnus Åbrink; David M Lee; Susan M Schlenner; Thorsten B Feyerabend; Hans-Reimer Rodewald; Boris Turk; Sara Wernersson; Gunnar Pejler
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

3.  Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.

Authors:  Astri J Meen; Inger Øynebråten; Trine M Reine; Annette Duelli; Katja Svennevig; Gunnar Pejler; Trond Jenssen; Svein O Kolset
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

4.  Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  Lu He; Xinke Zhou; Chen Qu; Yunqiang Tang; Qiong Zhang; Jian Hong
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

Review 5.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 6.  Matrix proteoglycans in tumor inflammation and immunity.

Authors:  Gauri Deb; Alexander Cicala; Athanasios Papadas; Fotis Asimakopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

7.  The proteoglycan repertoire of lymphoid cells.

Authors:  Bodil Fadnes; Anne Husebekk; Gunbjørg Svineng; Øystein Rekdal; Masaki Yanagishita; Svein O Kolset; Lars Uhlin-Hansen
Journal:  Glycoconj J       Date:  2012-07-10       Impact factor: 2.916

8.  Loss of Serglycin Promotes Primary Tumor Growth and Vessel Functionality in the RIP1-Tag2 Mouse Model for Spontaneous Insulinoma Formation.

Authors:  Andrew Hamilton; Vladimir Basic; Sandra Andersson; Magnus Abrink; Maria Ringvall
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 9.  Serglycin: at the crossroad of inflammation and malignancy.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Vassiliki T Labropoulou; Gianna Smirlaki; Argyrios Noulas; Nikos K Karamanos; Achilleas D Theocharis
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

10.  Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma.

Authors:  Ananya Roy; Julia Femel; Elisabeth J M Huijbers; Dorothe Spillmann; Erik Larsson; Maria Ringvall; Anna-Karin Olsson; Magnus Åbrink
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.